Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H22N2O3 |
Molecular Weight | 266.3361 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1C(=O)NC(=O)N(C2CCCCC2)C1=O
InChI
InChIKey=DVEQCIBLXRSYPH-UHFFFAOYSA-N
InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19)
Molecular Formula | C14H22N2O3 |
Molecular Weight | 266.3361 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/10497145Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661
Bucolome (Paramidine) is a barbiturate derivative. It is a non-steroidal anti-inflammatory drug, which is used in the treatment of chronic articular rheumatism. It has been used as a uricosuric and/or anti-inflammatory agent in Japan since 1967. Bucolome acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3397 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145 |
8.24 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PARAMIDIN Approved UseAntirheumatic and antigout drug |
PubMed
Title | Date | PubMed |
---|---|---|
Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. | 2005 Apr |
|
[Intraluminal ureteral hematoma complicating anticoagulant therapy]. | 2005 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11304904
300 mg dose of bucolome once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/15640375
Protein binding of furosemide (20 M) was significantly inhibited by 300 M
bucolome in human serum
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:30:22 GMT 2023
by
admin
on
Fri Dec 15 16:30:22 GMT 2023
|
Record UNII |
9T08RAL174
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
31314
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
2284
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
3044
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106136
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
C084817
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
100000085847
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
9T08RAL174
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
BUCOLOME
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
C73080
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
2461
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
212-666-1
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
841-73-6
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
m2745
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID4048854
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY | |||
|
SUB05950MIG
Created by
admin on Fri Dec 15 16:30:23 GMT 2023 , Edited by admin on Fri Dec 15 16:30:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |